
GPCR Stock Forecast & Price Target
GPCR Analyst Ratings
Bulls say
Structure Therapeutics is poised for success with their promising weight loss drug, aleniglipron, and the upcoming FDA End-of-Phase-2 meeting in 2026 is a key milestone. The company's focus on dose selection, comparator requirements, and cardiovascular outcomes trial timing for their oral GLP-1s demonstrates their dedication to delivering safe and effective treatments for chronic diseases. The recent acquisitions of Carmot and Eccogene have bolstered their capabilities and made them an attractive target for acquisition in the competitive obesity market.
Bears say
Structure Therapeutics is a clinical stage biopharmaceutical company with a pipeline of small-molecule therapeutics aimed at treating chronic diseases. With promising Phase 2 data for its lead drug, aleniglipron, and a novel oral amylin program in development, there is increased interest and potential for significant return for investors. However, there are potential risks, such as failure in clinical studies or competition in the overcrowded obesity market, that could impact the company's success. Additionally, while potential for acquisition by larger pharma companies exists, it is uncertain who the potential acquirer would be at this time.
This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
GPCR Analyst Forecast & Price Prediction
Start investing in GPCR
Order type
Buy in
Order amount
Est. shares
0 shares